Literature DB >> 30518679

Inhibition of stromal cell-derived factor-1α/CXCR4 signaling restores the blood-retina barrier in pericyte-deficient mouse retinas.

Keisuke Omori1, Nanae Nagata1, Kaori Kurata2, Yoko Fukushima3, Erika Sekihachi1, Nobutaka Fujii4, Tomoko Namba-Hamano5, Yoshitsugu Takabatake5, Marcus Fruttiger6, Takashi Nagasawa7, Akiyoshi Uemura2, Takahisa Murata1.   

Abstract

In diabetic retinopathy (DR), pericyte dropout from capillary walls is believed to cause the breakdown of the blood-retina barrier (BRB), which subsequently leads to vision-threatening retinal edema. While various proinflammatory cytokines and chemokines are upregulated in eyes with DR, their distinct contributions to disease progression remain elusive. Here, we evaluated roles of stromal cell-derived factor-1α (SDF-1α) and its receptor CXCR4 in the BRB breakdown initiated by pericyte deficiency. After inhibition of pericyte recruitment to developing retinal vessels in neonatal mice, endothelial cells (ECs) upregulated the expression of SDF-1α. Administration of CXCR4 antagonists, or EC-specific disruption of the CXCR4 gene, similarly restored the BRB integrity, even in the absence of pericyte coverage. Furthermore, CXCR4 inhibition significantly decreased both the expression levels of proinflammatory genes (P < 0.05) and the infiltration of macrophages (P < 0.05) into pericyte-deficient retinas. Taken together, EC-derived SDF-1α induced by pericyte deficiency exacerbated inflammation through CXCR4 in an autocrine or paracrine manner and thereby induced macrophage infiltration and BRB breakdown. These findings suggest that the SDF-1α/CXCR4 signaling pathway may be a potential therapeutic target in DR.

Entities:  

Keywords:  Chemokines; Inflammation; Macrophages; Ophthalmology; endothelial cells

Mesh:

Substances:

Year:  2018        PMID: 30518679      PMCID: PMC6328022          DOI: 10.1172/jci.insight.120706

Source DB:  PubMed          Journal:  JCI Insight        ISSN: 2379-3708


  41 in total

1.  Retinal vascular patterns. IV. Diabetic retinopathy.

Authors:  D G COGAN; D TOUSSAINT; T KUWABARA
Journal:  Arch Ophthalmol       Date:  1961-09

2.  Sustained inflammation after pericyte depletion induces irreversible blood-retina barrier breakdown.

Authors:  Shuntaro Ogura; Kaori Kurata; Yuki Hattori; Hiroshi Takase; Toshina Ishiguro-Oonuma; Yoonha Hwang; Soyeon Ahn; Inwon Park; Wataru Ikeda; Sentaro Kusuhara; Yoko Fukushima; Hiromi Nara; Hideto Sakai; Takashi Fujiwara; Jun Matsushita; Masatsugu Ema; Masanori Hirashima; Takashi Minami; Masabumi Shibuya; Nobuyuki Takakura; Pilhan Kim; Takaki Miyata; Yuichiro Ogura; Akiyoshi Uemura
Journal:  JCI Insight       Date:  2017-02-09

Review 3.  Novel approaches for treating diabetic retinopathy based on recent pathogenic evidence.

Authors:  Rafael Simó; Cristina Hernández
Journal:  Prog Retin Eye Res       Date:  2015-04-30       Impact factor: 21.198

4.  CCR2 expression by brain microvascular endothelial cells is critical for macrophage transendothelial migration in response to CCL2.

Authors:  Kirk A Dzenko; Li Song; Shujun Ge; William A Kuziel; Joel S Pachter
Journal:  Microvasc Res       Date:  2005-05-31       Impact factor: 3.514

5.  Tlx acts as a proangiogenic switch by regulating extracellular assembly of fibronectin matrices in retinal astrocytes.

Authors:  Akiyoshi Uemura; Sentaro Kusuhara; Stanley J Wiegand; Ruth T Yu; Shin-ichi Nishikawa
Journal:  J Clin Invest       Date:  2006-01-19       Impact factor: 14.808

6.  Endothelium-specific platelet-derived growth factor-B ablation mimics diabetic retinopathy.

Authors:  Maria Enge; Mattias Bjarnegård; Holger Gerhardt; Erika Gustafsson; Mattias Kalén; Noomi Asker; Hans-Peter Hammes; Moshe Shani; Reinhardt Fässler; Christer Betsholtz
Journal:  EMBO J       Date:  2002-08-15       Impact factor: 11.598

7.  Cellular niches controlling B lymphocyte behavior within bone marrow during development.

Authors:  Koji Tokoyoda; Takeshi Egawa; Tatsuki Sugiyama; Byung-Il Choi; Takashi Nagasawa
Journal:  Immunity       Date:  2004-06       Impact factor: 31.745

8.  Chemokine mediated monocyte trafficking into the retina: role of inflammation in alteration of the blood-retinal barrier in diabetic retinopathy.

Authors:  Sampathkumar Rangasamy; Paul G McGuire; Carolina Franco Nitta; Finny Monickaraj; Sreenivasa R Oruganti; Arup Das
Journal:  PLoS One       Date:  2014-10-20       Impact factor: 3.240

9.  Dipeptidyl Peptidase-4 Inhibitor Increases Vascular Leakage in Retina through VE-cadherin Phosphorylation.

Authors:  Choon-Soo Lee; Yun Gi Kim; Hyun-Jai Cho; Jonghanne Park; Heewon Jeong; Sang-Eun Lee; Seung-Pyo Lee; Hyun-Jae Kang; Hyo-Soo Kim
Journal:  Sci Rep       Date:  2016-07-06       Impact factor: 4.379

Review 10.  Moving Past Anti-VEGF: Novel Therapies for Treating Diabetic Retinopathy.

Authors:  Mark T Bolinger; David A Antonetti
Journal:  Int J Mol Sci       Date:  2016-09-07       Impact factor: 5.923

View more
  4 in total

Review 1.  The innate immune system in diabetic retinopathy.

Authors:  Warren W Pan; Feng Lin; Patrice E Fort
Journal:  Prog Retin Eye Res       Date:  2021-01-08       Impact factor: 19.704

Review 2.  CRISPR Gene Editing of Human Primary NK and T Cells for Cancer Immunotherapy.

Authors:  Ezgi Elmas; Noushin Saljoughian; Marcelo de Souza Fernandes Pereira; Brian P Tullius; Kinnari Sorathia; Robin J Nakkula; Dean A Lee; Meisam Naeimi Kararoudi
Journal:  Front Oncol       Date:  2022-04-05       Impact factor: 5.738

Review 3.  Pyroptosis in the Retinal Neurovascular Unit: New Insights Into Diabetic Retinopathy.

Authors:  Chunren Meng; Chufeng Gu; Shuai He; Tong Su; Thashi Lhamo; Deji Draga; Qinghua Qiu
Journal:  Front Immunol       Date:  2021-10-19       Impact factor: 7.561

4.  Myometrial-derived CXCL12 promotes lipopolysaccharide induced preterm labour by regulating macrophage migration, polarization and function in mice.

Authors:  Lijuan Zhang; Ramanaiah Mamillapalli; Shutaro Habata; Molly McAdow; Hugh S Taylor
Journal:  J Cell Mol Med       Date:  2022-03-23       Impact factor: 5.295

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.